Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #1 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

NCT02108418
View directory record Official record
Conditions
Healthy
Interventions
TG-2349 as the original formulation, TG-2349 as a new capsule formulation
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Results available

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

NCT05013424
View directory record Official record
Conditions
Glabellar Lines
Interventions
Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Glendale, Arizona • Coral Gables, Florida • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations

NCT00612768
View directory record Official record
Conditions
Dermatitis, Contact
Interventions
TRUE Test allergens Fragrance Mix and Thimerosol
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study

NCT03555617
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
TD-1473, Itraconazole
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

NCT03978143
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 3 Interventional

Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

NCT00744016
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Granulated mesalamine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bristol, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Results available

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

NCT03315104
View directory record Official record
Conditions
Influenza A H3N2, Influenza A H1N1
Interventions
FLU-IGIV, Placebo for FLU-IGIV
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

NCT02197416
View directory record Official record
Conditions
Venous Thromboembolism, Secondary Prevention
Interventions
dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Up to 18 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
9
States / cities
Sacramento, California • Miami, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 31, 2026, 11:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

NCT00224484
View directory record Official record
Conditions
Herpes Simplex
Interventions
GSK208141, Havrix (investigational formulation), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years · Female only
Enrollment
5,960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

NCT02672839
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
LGD-6972 Solution, LGD-6972 Capsules
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 31, 2026, 11:41 AM EDT
Not yet recruiting Phase 2 Interventional

Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome

NCT07768267
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions
Biocidin REMOVE, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00313599
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
lapatinib, paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

NCT03448172
View directory record Official record
Conditions
Healthy
Interventions
[14C]PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

NCT02497716
View directory record Official record
Conditions
Thrombosis
Interventions
Rivaroxaban (Xarelto, BAY59-7939
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Months to 12 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Oakland, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

NCT06828055
View directory record Official record
Conditions
Weight Loss
Interventions
Placebo, VK2735
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Peoria, Arizona • Lake Forest, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

NCT03677934
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
77
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 31, 2026, 11:41 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132
View directory record Official record
Conditions
Generalized Epidermolysis Bullosa Simplex
Interventions
AC-203, Vehicle
Drug
Lead sponsor
TWi Biotechnology, Inc.
Industry
Eligibility
6 Months and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Ixekizumab in Healthy Participants

NCT03848416
View directory record Official record
Conditions
Healthy
Interventions
Ixekizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants

NCT04565678
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Mitapivat tablets, Mitapivat coated granules
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors

NCT00132158
View directory record Official record
Conditions
Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma
Interventions
Irinotecan (Camptosar), Gefitinib (Iressa)
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

NCT06477926
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-668 IR, ABBV-668 ER
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 31, 2026, 11:41 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

NCT06337643
View directory record Official record
Conditions
Pneumococcal Vaccine
Interventions
MVX01, MVX01 Placebo
Biological
Lead sponsor
Matrivax Research and Development Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Savannah, Georgia • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 31, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

NCT03254784
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165 Capsule, BMS-986165 Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 31, 2026, 11:41 AM EDT